Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen will get KAI’s late-stage-ready asset for a small upfront price and gives itself a logical line extension to its chronic kidney disease drug Sensipar.
You may also be interested in...
Amgen Gets Parsabiv CRL, Gives No Clues As To Why
FDA issued a complete response letter for the Sensipar follow-on, and Amgen declined to provide any details about the reason why or timeline for resubmission.
Amgen Files NDA For I.V. Rival To Sensipar
The calcimimetic etelcalcetide could be administered intravenously following dialysis sessions for chronic kidney disease patients with secondary hyperparathyroidism, eliminating the high pill burden associated with Sensipar.
Amgen’s KAI Deal Pays Off With Positive Phase III Trial Of Sensipar Successor
Drug acquired for $315 million in cash from KAI in 2012 – AMG 416 – hits all primary and secondary endpoints in first pivotal study of hyperparathyroidism in dialysis patients; two other trials have yet to report.